S'abonner

Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case–control study - 26/09/12

Doi : 10.1016/S1470-2045(08)70038-X 
Lee E Moore, DrPhD a, , Ruth M Pfeiffer, PhD a, Cristina Poscablo, BS a, Francisco X Real, MD c, Manolis Kogevinas, MD d, Debra Silverman, ScD a, Reina García-Closas, MD e, Stephen Chanock, MD b, Adonina Tardón, PhD f, Consol Serra, MD g, Alfredo Carrato, ProfMD h, Mustafa Dosemeci, PhD a, Montserrat García-Closas, MD a, Manel Esteller, MD c, Mario Fraga, PhD c, Nathaniel Rothman, MD a, Núria Malats, MD c
a Division of Cancer Epidemiology and Genetics, National Cancer Institute, Department of Health and Human Services, Rockville, MD, USA 
b Core Genotyping Facility, Advanced Technology Center, National Cancer Institute, Department of Health and Human Services, Rockville, MD, USA 
c Spanish National Cancer Research Centre (CNIO) Madrid, Spain 
d Research Centre in Environmental Epidemiology, Medical Research Institute (IMIM), Barcelona, Spain, Medical School, University of Crete, Greece, and CIBER Epidemiology and Public Health, Spain 
e University Hospital of Canarias, La Laguna, Spain 
f University of Oviedo, Oviedo, Spain 
g Consorci Hospitalari Parc Taulí, Sabadell, Spain, and University Pompeu Frabra, Barcelona, Spain 
h University Hospital of Elche, Elche, Spain 

* Correspondence to: Dr Lee E Moore, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD, USA

Summary

Background

DNA hypomethylation has been suggested to cause genomic instability and increase cancer risk. We aimed to test the hypothesis that DNA hypomethylation is associated with increased risk of bladder cancer.

Methods

We measured cytosine methylation (5-mC) content in genomic DNA from blood cells from patients with bladder cancer enrolled in a large case–control study in Spain between Jan 1, 1998, and Dec 31, 2001. Cases were men and women with newly diagnosed and histologically confirmed urothelial carcinoma of the bladder. Controls were selected from patients admitted to the same hospital for diseases or conditions unrelated to smoking or other known risk factors for bladder cancer. Controls were individually matched to cases on age (within 5 years), sex, race, and area of hospital referral. 5-mC content was measured in leucocyte DNA by use of a combination of high-performance capillary electrophoresis, Hpa II digestion, and densitometry. Data on demographics, 34 polymorphisms in nine folate metabolism genes, and nutritional intake of six B vitamins (including folate), alcohol, and smoking were assessed as potential confounders. Relative 5-mC content was expressed as a percentage (%5-mC) with respect to the total cytosine content (the sum of methylated and non-methylated cytosines). The primary endpoint was median %5-mC DNA content.

Findings

%5-mC was measured in leucocyte DNA from 775 cases and 397 controls. Median %5-mC DNA was significantly lower in cases (3·03% [IQR 2·17–3·56]) than in controls (3·19% [2·46–3·68], p=0·0002). All participants were subsequently categorised into quartiles by %5-mC content in controls. When the highest quartile of %5-mC content was used as the reference category (Q4), the following adjusted odds ratios (OR) and 95% CI were recorded for decreasing methylation quartiles: OR(Q3) 2·05 (95% CI 1·37–3·06); OR(Q2) 1·62 (1·07–2·44); and OR(Q1) 2·67 (1·77–4·03), p for trend <0·0001. The lowest cancer risk was noted in never smokers in the highest methylation quartile (never smokers in Q4). By comparison with never smokers in the highest quartile, current smokers in the lowest methylation quartile had the highest risk of bladder cancer (Q1: OR 25·51 [9·61–67·76], p for interaction 0·06). In analyses stratified by smoking, hypomethylation was a strong risk factor in never smokers (OR 6·39 [2·37–17·22]). Amount of methylation in controls were not associated with baseline characteristics, micronutrients, or selected genotypes in folate metabolism pathways.

Interpretation

For the first time, to our knowledge, we have shown in a large case–control study that leucocyte DNA hypomethylation is associated with increased risk of developing bladder cancer, and this association is independent of smoking and the other assessed risk factors. Amount of global methylation in genomic DNA could provide a useful biomarker of susceptibility to certain cancer types and further research is warranted.

Funding

Intramural Research Program of the National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, MD, USA, and Fondo de Investigacion Sanitaria, Spain (G03/174).

Le texte complet de cet article est disponible en PDF.

Plan


© 2008  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 9 - N° 4

P. 359-366 - avril 2008 Retour au numéro
Article précédent Article précédent
  • Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ)
  • Pier Luigi Zinzani, Monica Tani, Alessandro Pulsoni, Marco Gobbi, Alessio Perotti, Stefano De Luca, Alberto Fabbri, Alfonso Zaccaria, Maria Teresa Voso, Pierpaolo Fattori, Luciano Guardigni, Sonia Ronconi, Maria Giuseppina Cabras, Luigi Rigacci, Amalia De Renzo, Enrica Marchi, Vittorio Stefoni, Mariapaola Fina, Cinzia Pellegrini, Gerardo Musuraca, Enrico Derenzini, Stefano Pileri, Stefano Fanti, Pier Paolo Piccaluga, Michele Baccarani
| Article suivant Article suivant
  • Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies
  • Liv Veldeman, Indira Madani, Frank Hulstaert, Gert De Meerleer, Marc Mareel, Wilfried De Neve

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.